Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Up 8% – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price shot up 8% during trading on Thursday . The stock traded as high as $114.49 and last traded at $114.49. 337 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,958 shares. The stock had previously closed at $106.00.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Stock Performance

The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $112.06 and a two-hundred day simple moving average of $118.38.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.